These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1903913)

  • 1. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Mar; 35(3):587-9. PubMed ID: 1903913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
    Waites KB; Duffy LB; Schmid T; Crabb D; Pate MS; Cassell GH
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1181-5. PubMed ID: 1929260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1515-6. PubMed ID: 1929320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.
    Cassell GH; Waites KB; Pate MS; Canupp KC; Duffy LB
    Diagn Microbiol Infect Dis; 1989; 12(5):433-5. PubMed ID: 2515025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1726-7. PubMed ID: 8215294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M; Ishida K; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
    Cohen MA; Huband MD
    J Antimicrob Chemother; 1997 Aug; 40(2):308-9. PubMed ID: 9302005
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    J Antimicrob Chemother; 1994 Dec; 34(6):875-83. PubMed ID: 7730231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antimicrobial activities of new quinolone antibiotics against Mycoplasma pneumoniae].
    Gohara Y; Arai S; Kuwano K; Kawashima T; Matsu-Ura I
    Nihon Saikingaku Zasshi; 1992 Mar; 47(2):387-93. PubMed ID: 1318981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro activity of sparfloxacin against mycoplasmas].
    Renaudin H; Bebear C
    Pathol Biol (Paris); 1992 May; 40(5):450-4. PubMed ID: 1323094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.
    Furneri PM; Bisignano G; Cerniglia G; Nicoletti G; Cesana M; Tempera G
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2651-4. PubMed ID: 7872762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():226-7. PubMed ID: 8549311
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activities of five quinolones against Chlamydia pneumoniae.
    Hammerschlag MR; Hyman CL; Roblin PM
    Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.